Skip to Main Content


Skip Nav Destination
Issue Cover
Current Issue
Volume 12,
Issue 9
1 September 2022

About the Journal

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal

Noted This Week

The FDA granted accelerated approval to selpercatinib (Retevmo; Eli Lilly) to treat adults with locally advanced or metastatic solid tumors with a RET gene fusion whose cancer has advanced on or after a systemic treatment or who have no other satisfactory therapeutic options. Data from the LIBRETTO-001 trial showed that selpercatinib yielded clinically meaningful and durable responses across a variety of tumor types, including pancreatic and colon cancers, in patients with RET-driven malignancies. The agency also granted regular approval to selpercatinib for the treatment of adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with a RET gene fusion; the drug had received accelerated approval for this indication in 2020.

More Noted This Week, September 16–22   »

Close Modal

or Create an Account

Close Modal
Close Modal